Lansoprazole Mylan

Lansoprazole, the active ingredient in Lansoprazole Mylan, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid production and is used to treat conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease, and erosive esophagitis in adult patients.

GNH USA supplies Lansoprazole Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Lansoprazole is indicated for several acid‑related gastrointestinal conditions.

- Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by reducing acid exposure. - Peptic ulcer disease: promotes ulcer healing by maintaining a higher gastric pH. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotics by suppressing acid. - Erosive esophagitis: facilitates mucosal recovery by limiting further acid damage.

Lansoprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: watery stools, usually transient. - Nausea: occasional upset stomach. - Abdominal pain: cramping or discomfort. - Flatulence: increased gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Severe allergic reactions (anaphylaxis): rash, swelling, airway compromise. - Hypomagnesemia: low serum magnesium with prolonged use. - Vitamin B12 deficiency: malabsorption over long term. - Increased risk of bone fracture: reduced calcium absorption. - Acute interstitial nephritis: renal inflammation presenting with fever and eosinophilia.

Before prescribing Lansoprazole, clinicians should consider several safety precautions.

- Assess renal function: adjust use in severe impairment. - Monitor bone health: long‑term therapy may affect calcium absorption. - Evaluate for H. pylori infection: consider eradication regimens when appropriate. - Avoid abrupt discontinuation: taper to prevent rebound acid hypersecretion. - Store at ambient temperature: keep in the original pack, protect from moisture.

Lansoprazole can affect the plasma concentrations of several concomitant medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir: markedly decreased absorption, compromising antiviral efficacy. - Ketoconazole: substantially reduced exposure, limiting antifungal activity.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum levels, risk of toxicity. - Methotrexate (high dose): reduced clearance, potential for accumulation. - Iron salts: decreased absorption, may require separate dosing times.